Oregon to crack down on illegal pot growers by holding landowners responsible

By Andrew Selsky

(AP) Salem, Ore. — Oregon has long been known as a mecca for high-quality marijuana, but that reputation has come with a downside: illegal growers who offer huge amounts of cash to lease or buy land and then leave behind pollution, garbage and a drained water table.

Now, a bill passed by the Oregon Legislature seeks to tackle that by making the landowners themselves responsible for the aftermath. The bill also prohibits the use of rivers or groundwater at the illegal site, as well as criminalizes seizing the identity papers of migrant workers who tend the plants or threatening to report them for deportation.

Under the bill, local governments are authorized to file a claim of lien against property used for illicit marijuana, if the owner doesn’t pay for the cleanup.

Advertisement

A leader of the state’s cannabis and alcohol regulatory agency has said southern Oregon is to marijuana what Bordeaux is to wine. But the state faces challenges on two fronts: The regulated industry has a glut of product that has slashed prices and profit margins, and there has been huge growth in illegal pot farms operating under the guise of growing hemp, which became legal nationally in 2018.

After passing the Senate and House, the House Speaker Dan Rayfield signed the measure Wednesday, over the objections of some Republicans. Democratic Gov. Tina Kotek is expected to sign it next week.

“This is just an assault on property rights here in the state of Oregon,” GOP Sen. Dennis Linthicum said on the Senate floor.

But Sen. Jeff Golden, of Ashland, said property owners should know something is amiss when they are “approached at the beginning of the growing season with requests to lease their property for tens, sometimes hundreds of thousand dollars for a single year.”

Witnesses have described backpacks with thousands of dollars in cash being handed over to landowners and getting numerous offers to buy.

“We pay CASH and offer a fast close,” says one letter received by a landowner last year, one of three offers.

Jackson County Sheriff Nathan Sickler told lawmakers that after police raid illegal pot farms, neither landowners nor the suspects make efforts to remove the cheaply built greenhouses, known as “hoop houses,” latrines, and other debris, including plastics and chemicals.

“Frankly, it’s an eyesore for our community, with no means to deal with it,” Sickler said.

Some two years ago, the ideal growing conditions began attracting criminal gangs from Mexico, Russia and other countries, police said. Thousands of hoop houses cropped up and police were overwhelmed, nailing only a fraction of the sites. Workers at these farms often live in squalid conditions and use open latrines, and they are sometimes cheated out of their pay.

Due to persistent police raids, which netted over 100 tons of illegal marijuana across the state last year, the grow sites have become smaller and more dispersed. For example, on Thursday, Josephine County Sheriff’s deputies and other officers raided a property in Cave Junction and destroyed about 2,000 marijuana plants and 100 pounds of processed marijuana.

Landowners who have been intimidated and suffered environmental damage from illegal grow sites are applauding the bill.

“At least most of the landowners knew what they were doing was wrong. I believe this measure will help to stem the tide,” said Jack Dwyer, who has a house near the community of Selma. In 2021, Dwyer said a large illegal grow site nearby siphoned all the water from a creek that runs through his property, causing it to run dry.

Christopher Hall, who works to engage the public in water stewardship, said the bill shows that Oregon officials understand the problem of large-scale illicit cannabis operations and are committed to solving it.

The illicit sites “not only turn streams into gravel roads but also lead to serious human rights violations and dumping of trash, sewage, chemicals, and other waste into ditches, riparian areas, and streams,” he said.

The Senate approved the measure before GOP senators began a walkout on May 3 over Democratic measures on abortion, gender-affirming care and gun safety. The House passed the marijuana bill on a 53-3 vote on May 31. The bill will now go to Kotek to sign into law, taking immediate effect.

“The governor supports cracking down on illegal cannabis operations that have been prevalent in southern Oregon,” said Elisabeth Shepard, Kotek’s spokesperson.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

image
  • Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease
  • This has been termed as “the most convincing evidence in humans,” ultimately showcasing the potential of the company’s patented DehydraTECH(TM)-processed CBD
  • Other third-party research studies have failed to demonstrate a sustained decrease in resting blood pressure with oral CBD dosing. More so, none have yielded evidence of the anti-inflammatory actions of CBD until Lexaria’s HYPER-H21-4 human clinical study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its HYPER-H21-4 human clinical study that sought to explore the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) in reducing blood pressure (“BP”). Of note was the demonstration of significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease (“CVD”) in what was described as “the most convincing evidence in humans” of the anti-inflammatory actions of CBD.

“There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” noted Dr. Philip Ainslie, Cardiovascular Advisor to Lexaria and Lead Investigator of Study HYPER-H21-4 (https://cnw.fm/UQFIv).

This finding adds to the success of the ambitious HYPER-H21-4, which successfully met all primary efficacy and safety objectives, with resting BP showing a significant reduction among hypertensive patients. Furthermore, this reduction in BP was sustained over a full 5-weeks of dosing, with no serious adverse events reported.  This built on the findings from the four previous human clinical studies conducted from 2018 to 2022, all of which have paved the way for Lexaria’s anticipated U.S. Food and Drug Administration (“FDA”) HYPER-H23-1 clinical study, its most ambitious yet.

Titled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” HYPER-H23-1 looks to build on all previous studies conducted by Lexaria thus far. It also plays an integral role as a lead-up to IND filing this summer, with hopes for FDA authorization within 60 days after that.

So far, only a handful of other research studies have investigated whether a sustained decrease in resting blood pressure is possible following multiple weeks of oral CBD dosing. However, none have been successful at achieving it. More so, none have yielded evidence of the anti-inflammatory actions of CBD, which shows the potential of Lexaria’s DehydraTECH-CBD.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lift Toronto 2023 engages 1000’s of cannabis professionals, companies and the community to grow the industry

Toronto — With the five-year mark for federal legalization on the horizon, the Canadian cannabis industry is experiencing a critical period. From June 1-3, Lift Toronto 2023 welcomed professionals from each segment of the cannabis ecosystem, along with supporters and consumers, to discover new products and innovations, experience Lift’s signature ah-ha! moments, and immerse in three days of leading-edge content focused on the future of cannabis from diverse points of view.

“The first Lift was in 2015, and since then, it’s been with the Canadian cannabis industry every step of the way. Our events provide a forum for celebration and support. While the balance between the two shifts, depending on the needs and challenges of the community, our purpose remains the same: to produce an amazing event for our partners, exhibitors and attendees.” — Lindsay Roberts, portfolio lead, Lift Events & Experiences

New for Toronto 2023, two sets of grants for micro-growers and independent retailers, as well as 30 budtender educational scholarships were sponsored by the Ontario Cannabis Store (OCS). David Lobo, president & CEO of OCS, also delivered the keynote address to open the Lift Cannabis Business Conference on Thursday, June 1. “Cannabis is a movement, not just a market,” said Lobo, setting the tone for a day of advocacy-oriented, strategy-focused speakers and panels.

The event continued through Friday, June 2 and Saturday, June 3, with a multi-neighborhood expo, four stages packed with content, and Lift’s signature activations and attractions. High points included the brand-new Diners’ Club with live food and beverage demonstrations, two Speakers’ Corner small group discussion areas, expanded budtender and consumer programs, interactive networking areas and plenty of opportunities for new product discovery.

Advertisement

Lift Toronto 2023 Highlights

  • 3,000+ attendees
  • 140+ speakers featured in 45 educational sessions, demonstrations and panels
  • Strategy-focused and advocacy-oriented Lift Cannabis Business Conference
  • Expo showcasing 100+ exhibiting companies from across the cannabis ecosystem
  • Micro-Grower, Independent Retailer & Budtender Grant Awards
  • Budtender appreciation program including free entry, dedicated lounge area and Budtender Masterclass education.
  • Consumer-focused features including PLAY@Lift with games and photo opps, and live entertainment from The Noobie and The Doobie’s Timmy Boyle and Marijane Baker.
  • All-new Diner’s Club featuring the hottest culinary cannabis trends and insights.
  • Lift After Party at Steam Whistle Brewing with music, drinks, bites and networking to end the show on a high note.

Micro-Grower Grant Winners

  • Bob’s Better Buds
  • Primeau Cannabis
  • The Cultivarium
  • Treez Botanical, Inc.

Independent Retailer Grant Winners

  • Ingram & Sons Cannabis Co.
  • Purple Tree Cannabis
  • ROLL’D Cannabis Co.
  • Shivaa’s Rose

Lift Industry Attendees Snapshot

  • 27 per cent own or represent LP’s
  • 48 per cent c-suite, owner or founder
  • 54 per cent purchasing decision-makers
  • 80 per cent plan to follow up with exhibitors after the show

“Now more than ever, in-person events like Lift are crucial for the industry,” said Roberts. “You could feel the positive energy at the conference, on the expo floor, and at the Lift After Party. We were grateful to be able to bring the community together for important conversations about the challenges and opportunities that lay ahead. Lift Toronto was an inclusive, meaningful and uplifting experience that won’t soon be forgotten.”

Upcoming Events:

Lift San Francisco 2023: August 3-4, 2023 | Moscone Center
Tickets are on sale now and prime partnerships are still available for the Lift Events & Experiences U.S. debut. Lift San Francisco Exhibits & Partnerships

Experiment In Progress: Neurological Damage

Experiment In Progress: Neurological Damage

www.natureofhealing.org

Experiment In Progress: Neurological Damage

By

In December of 2019, COVID-19 made its world debut and took center stage as “the deadly contagion.” The strategy to build fear was the key that aligned world governments as one united force. For the first time in history, a virus became the trigger for the acceptance of a global vaccine.

Ironically, at that time, the coronavirus had not been isolated.

The Bluff

“Hegelian dialectic, or problem, reaction, solution. This method basically involves fabricating or intensify a problem, offering a draconian solution, then settling for a “compromise” that nevertheless furthers the intended goal.”
― Jim Marrs, author

Image by Gerd Altmann from Pixabay

To this day, Coronavirus (Cov-19), has not been isolated.

Buried in a PDF CDC document on page 41, the CDC admits that, “no quantified virus isolates of the 2019-nCoV are currently available”, and used a genetically modified human lung alveolar adenocarcinoma cell culture to, “mimic clinical specimen.”

As it turns out, the only isolate is a lab-produced and patented SARS Cov-2, part of the experimental mRNA injections created as gene therapy.

Thus, is the COVID-19 strategy based on a lie?  A September 2020 letter to the editor in the British Medical Journal connects some dots and calls out the bluff:

Rapid Response:
Re: Covid-19: Where is the virus?

Dear Editor

We are told that the virus is everywhere – in the air, in our breath, on fomites, trapped in masks – yet public health authorities seem not to be in possession of any cultivable clinical samples of the offending pathogen.

In March 2020, the World Health Organisation instructed authorities not to look for a virus but to rely instead on a genome test, the RT-PCR, which is not specific for SARS-CoV-2 (1) (2).

However, RT-PCR does not distinguish between infectious and non-infectious virus. Propagating virus from clinical samples confirms the presence of infectious virus but is not widely available (and) requires biosafety level 3 facilities” (4).

It appears, therefore, that we have public health bodies without clinical samples, a test which is non-specific and does not distinguish between infectivity and non-infectivity, a requirement for biosafety level 3 facilities to even look for a virus, yet we are led to believe that it is up all our noses.

So, where is the virus?

The Set Up

When world governments synchronized to fight the “deadly coronavirus,” they unilaterally agreed to deploy experimental injections without any verifiable threat and only limited, short term data.  The medical narrative explained:

The drama of the pandemic has forced the scientific community to accelerate the development and commercialization of vaccines, thereby enhancing the phases of active surveillance.

In 2019. then-president Trump paved the way for the U.S. deployment of experimental vaccines on a trusting public via two Executive Orders, bypassing Congress and the legal process: a September 2019 Executive Order and a December 2020 Executive Order.

On March 20, 2020, during a White House briefing on COVID, Secretary Mike Pompeo disclosed COVID as a live exercise.

We’re in a – we’re in a live exercise here to get this right.  – Secretary Mike Pompeo

In February 2021, The U of Chicago Medicine warned people with autoimmunity about experimental vaccines on its website, but doctors did not get the memo:

No data exists on the (COVID) vaccines’ effectiveness in immunocompromised patients because they weren’t included in the initial clinical trials. This is true of all vaccine trial studies.

In April 2023, buried in correspondence to vaccine makers, the FDA disclosed that it required years of additional safety studies on all mRNA vaccines thru 2027. Thus, the FDA only renewed Pfizer’s Emergency Use Authorization (EUA) COVID-19 vaccine. The formal FDA approval was for BioNTech’s Comirnaty vaccine. which is used in Europe, not in the U.S.

Throughout the live exercise, State governors declared illegal “emergency” mandates onto an unsuspecting public. People were ignorant of the consequences of a vaccine that had never been formally tested. Most people never knew they signed on as subjects of an ongoing governmental experiment.

imageVinzenz Lorenz M from Pixabay” width=”300″ height=”200″>

In short order, fifteen COVID-19 injections were granted “emergency-use authorization.” They were not FDA-approved. The CDC and FDA rushed the injections to market before the completion of conventional phases of clinical trials. Never before had science been so propagandized, and health been so ignored.

Looking back, had a military operation been disguised as a Public Health threat? Did the people who perceived a threat know that vaccine makers came with criminal records and full immunity for any injuries or deaths resulting from their products?

Is this live exercise a crime against humanity?

Tracking Collateral Damage

After the mRNA therapies were rolled out, The World Heath Organization (WHO), set up tracking for adverse events (AEs), using its VigiBase global database. Unfortunately, the VigiBase system is a passive system, dependent on national centers for the timeliness, completeness, and quality of reports.

VigiBase is a global pharmacovigilance database established in 1978 and consists of over 20 million reports of suspected adverse events reported since its origin by its 130 member countries which represent 90% of the world population

Using the VigiBase, one 2022 study published in the Journal Cureus, analyzed neurological AEs between December 15, 2020 to January 24, 2021. The authors wrote:

 In this period, 103,954 adverse events were reported from 30,532 subjects who were administered the COVID-19 vaccine. Out of 103,954, 19,529 AEs were related to clinical events and investigations related to the neurological system.

The following AEs are only a few that are considered to be associated with the administration of the experimental mRN injections:

ageusia, allodynia, anesthesia, anosmia, aura, balance disorders, Bell’s palsy, burning sensation, cervicobrachial syndrome, cerebral venous sinus thrombosis, cluster headache, dizziness, postural dizziness, dysgeusia, exertional headache, facial paralysis, facial paresis, facial spasm, febrile convulsion, head discomfort, headache, hemiparaesthesia, hemiparesis, hyperaesthesis, hypersomnia, hypoaesthesia, hypogeusia, hyperresponsive to stimuli, hyposomnia, ischemic stroke, lethargy, loss of consciousness, migraine, migraine with aura, monoparesis, neuralgia, paraesthesia, paresis, parosmia, petit mal epilepsy, poor sleep quality, presyncope, seizure, sensory disturbance, sensory loss, sinus headache, syncope, taste disorder, tension headache, transient global amnesia, transient ischemic attack, tremor, tunnel vision.

Frequently observed adverse events following vaccinations were headache, vertigo/dizziness, paresthesia, hypoesthesia, lethargy, and migraine.

The U.S. uses a similar, passive reporting system called the VAERS Reporting System, overseen by the CDC and FDA. However, only about 1% of injuries/deaths are ever reported. This means that 5000 reports of death translate to 500,000 deaths.

History of Vaccine Injuries

With vaccination, we traded infectious disease for autoimmune disease. –  Anonymous

Since the introduction of vaccination, there has been a steady increase in the incidence of autoimmune diseases. Concomitantly, the incidence of most infectious diseases has declined. Some people call this dynamic The Hygiene Hypothesis. We are too clean for our own good. And it all began with the idea to kill off our microbes to prevent natural infections, which builds immunity.

Unfortunately, the rise in vaccination has equaled a rise autoimmune disease. This has been known since 2000. Once called Vacinosis, the name later changed to The ASIA Syndrome.

A.S.I.A. is “Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants.” Hint: Adjuvants are integral to vaccines. The result is the body’s creation of autoantibodies, or antibodies that attack Self, also known as autoimmune disease.

Since A.S.I.A. was first noted in 2011, the connection has been ignored by medical professionals. Also ignored? Vaccines have also been associated with CNS demyelinating syndromes, which affect the nervous system. Again, this is not discussed in medical circles.

Neurological Damage from mRNA

imageJan Felix Christiansen from Pixabay” width=”300″ height=”200″>

New vaccine studies on the experimental mRNA injections show damage to all biological systems  As expected, there is COVID-19-vaccine-induced autoimmunity. But people are now showing a dysregulation of the immune system and the production of myelin sheath antigens that target neurons and the nervous system.

Myelin sheath antigens contribute to demyelinating diseases and disorders, with hard-to-pronounce names and acronyms. These include: Multiple Sclerosis (MS), Acute Disseminated, Encephalomyelitis (ADEM), Balo’s Disease (Concentric Sclerosis), Charcot-Marie-Tooth Disease (CMT), Guillain-Barre Syndrome (GBS), HTLV-I Associated Myelopathy (HAM), Neuromyelitis Optica (Devic’s Disease), Acute Haemorrhagic Leucoencephalitis, Primary Sjögren’s syndrome (SS), Neuromyelitis Optica Spectrum Disorder (NMOSD)

Demyelinating Diseases:  any condition that causes damage to the protective covering (myelin sheath) that surrounds nerve fibers in your brain, the nerves leading to the eyes (optic nerves) and spinal cord. 

The most common symptoms of demyelinating disorders are:

The Studies

imageMasum Ali from Pixabay” width=”300″ height=”180″>

As expected, the list of vaccine-induced neurological damage from the medical literature continue to grow on every continent:

1.. Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review J Clin Pharmacol. March 2022

The most common neurological event was facial nerve palsy (50% of all events). Other less frequently reported events included the reactivation of herpes zoster, Guillain-Barre syndrome, other demyelinating diseases, and neuropathy.

2. A rare presentation of undiagnosed multiple sclerosis after the COVID-19 vaccine Case Reports. J Community Hosp Intern Med Perspect. November 2021

We present a rare case of a 32-year-old patient who presented with symptoms and suggestive of MS a few days after receiving the COVID vaccine.

3. Sudden sensorineural hearing loss after COVID-19 vaccination  Case Reports. Int J Infect Dis., December 2021

Otolaryngologic adverse events after COVID-19 vaccination were reported, including several cases of sudden sensorineural hearing loss (SSNHL). We report three patients with SSNHL within three days after COVID-19 vaccination and consider an association between them.

4. Multiple Sclerosis Disease-: Implications on the Risk of Infection and Future Vaccination CNS Drugs. September 2020

When the future SARS-CoV-2 vaccine becomes available, patients with multiple sclerosis should be advised that certain therapies may interfere with mounting a protective immune response to the vaccine and that serological confirmation of a response may be required after vaccination.

Also, Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review J Clin Neurosci. October 2022.

5. Covid-19 vaccination can induce multiple sclerosis via cross-reactive CD4+ T cells recognizing SARS-CoV-2 spike protein and myelin peptides World Health Organization, 2022

Qiu et al. isolated spike protein-activated T-cells from the blood and cerebrospinal fluid of the two patients with post-mRNA vaccine multiple sclerosis. They then screened such activated T-cells against a range of multiple sclerosis-related proteins. They found that such activated T-cells also reacted with myelin sheath proteins, namely: myelin basic protein (MBP), myelin oligodendrocyte glycoprotein,  (MOG), and proteolipid protein (PLP).

6.  The pituitary gland in SARS-CoV-2 infections, vaccinations, and post-COVID syndrome Elsevier. December 2023

This review shows that the pituitary gland can be involved in SARS-CoV-2 infections and can be a target of side effects to SARS-CoV-2 vaccinations and of long-COVID.

7. A review of neurological side effects of COVID-19 vaccination, European Journal of Medical Research. February 2023

vaccination can have an adverse event, especially on nervous system. The most important and common complications are cerebrovascular disorders including cerebral venous sinus thrombosis, transient ischemic attack, intracerebral hemorrhage, ischemic stroke, and demyelinating disorders including transverse myelitis, first manifestation of MS, and neuromyelitis optica.

8. Acute Vertigo After COVID-19 Vaccination: Case Series and Literature Review, Front Med (Lausanne).  January 2022

 In the period from May to July 2021, we evaluated 33 patients (mean age 54.3 ± 14.1) with “acute vertigo” post COVID-19 vaccination. Symptoms included 16 patients (48.5%) with objective vertigo, 14 patients (42.4%) with subjective vertigo, and 3 patients (9.1%) with dizziness.

9. Spectrum of neurological complications following COVID-19 vaccination. Neurological Sciences. October 2021

The most devastating neurological post-vaccination complication is cerebral venous sinus thrombosis. Cerebral venous sinus is frequently reported in females of childbearing age, generally following adenovector-based vaccination. Another major neurological complication of concern is Bell’s palsy that was reported dominantly following mRNA vaccine administration. Acute transverse myelitis, acute disseminated encephalomyelitis, and acute demyelinating polyneuropathy are other unexpected neurological adverse events that occur as result of phenomenon of molecular mimicry.

10. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection Nature Medicine. October 2021

There was a substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain–Barré syndrome (IRR, 5.25; 95% CI: 3.00–9.18).

11. Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience Otol Neurotol. October 2021

Symptoms included 25 patients (83.3%) with hearing loss, 15 (50%) with tinnitus, eight (26.7%) with dizziness, and five (16.7%) with vertigo.

12. COVID-19 vaccination unveiling subclinical Sjögren’s syndrome Clinical and Experimental Rheumatology. September 2021

We report the first case of subclinical SS to become clinically apparent  after severe immunethrombocytopenia (ITP) following administration of the first COVID-19 vaccine dose.  [Note a 2000 study in the journal Arthritis Rhum showed Sjogren’s syndrome occurring after Hep B vaccination].

13. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers

Commonly reported symptoms (occurrence in descending order) were soreness, fatigue, myalgia, headache, chills, fever, joint pain, nausea, muscle spasm, sweating, dizziness, flushing, feelings of relief, brain fogging, anorexia, localized swelling, decreased sleep quality, itching, tingling, diarrhoea, nasal stuffiness and palpitations.

14. Vestibular neuritis after COVID-19 vaccination Case Reports. Hum Vaccin Immunother. December 2021

Vestibular neuritis (VN) is an acute vestibular syndrome that causes acute and spontaneous vertigo due to unilateral vestibular deafferentiation, leading to nausea or vomiting and unsteadiness that can last from days to weeks. Reactivation of latent type 1 herpes simplex virus, autoimmune disorders, and microvascular ischemia are hypothesized to be etiologies.

15. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19 Neurol Sci. June 2021

We reported for the first time a case of neuromyelitis optica spectrum disorder (NMOSD) that developed after the first dose of inactivated virus vaccine for COVID-19. The patient developed mild fever, vomiting, diarrhea, and cough after receiving the first dose of inactivated virus vaccine. Two months later, she experienced dizziness and unsteady walking. MRI scanning of the brain revealed lesions in area postrema and bilateral hypothalamus, typical for NMOSD. Serum antibodies for AQP4, ANA, SSA, SSB, Ro-52, and p-ANCA were positive. The patient was diagnosed as AQP4-positive NMOSD with coexisting systemic autoimmunity.

16. Acute Vertigo After COVID-19 Vaccination: Case Series and Literature Review Front Med (Lausanne). January 2022

The 9 patients had an evoked nystagmus pathognomonic for benign paroxysmal positional vertigo; in the remaining 17 cases, peripheral vestibular dysfunction could be excluded and central disorder may be suggested. Due to the prevalence of nystagmus of non-peripheral origin, a central nervous system involvement could not be excluded.

17. Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review J Clin Pharmacol. March 2022

This review compiles clinical data from reports of diagnosed immune-related neurological events that have occurred after COVID-19 vaccine administration….The most common neurological event was facial nerve palsy (50% of all events). Other less frequently reported events included the reactivation of herpes zoster, Guillain-Barre syndrome, other demyelinating diseases, and neuropathy. The underlying mechanism was hypothesized to be related to vaccine-induced type 1 interferon production leading to decreased tolerance of the myelin sheath antigens.

Many other studies show evidence of damage to the cardiovascular system, In fact,  More studies coming to light show how the glands of the endocrine system, especially how the thyroid and pituitary (hyperpituitary) are affected, as well as the gonads, with evidence of premenstrual and menstrual changes from  endocrine disruption.  Additionally, skin manifestations and oral anomalies are documented.

All In Your Head?

imageMerlin Lightpainting from Pixabay” width=”300″ height=”200″>

Some ‘experts’ claim that post-COVID symptoms are “all in your head,” due to “stress.”

While stress can, indeed, affect the severity of any imbalance in the body, it does not explain thousands of studies, evaluating hundreds of people who are experiencing direct effects, post-mRNA injection. Be aware of attitudes like this one, blaming the patient for “perceived side effects“:

…if subjects are panicked, concerned, stressed or scared of the vaccination, their arteries will constrict and become smaller in and around the time of receiving the vaccine. This biological mechanism (the constriction of veins, arteries and vessels under mental stress) is the most likely cause for where there has been blood clots, strokes, heart attacks, dizziness, fainting, blurred vision, loss of smell and taste that may have been experienced shortly after vaccine administration.

Additionally, C19 vaccinated individuals who are completely asymptomatic have the same blood clotting findings as the vaccine injured.Clotting is worsened upon exposure to 5G frequencies or Pulsed Electromagnetic Fields (PEMF). [Read more about The SMART™ Evolution].

If symptoms are all in your head, then why are they being tracked and monitored through medical studies and databases?  Why are new sequelae of symptoms being christened with new names?  Why are new COVID treatments being publicized on TV?

Because, with the growth of SARS-Cov-2 vaccine-induced disorders, pharmaceutical drug companies see growth in their own bottom lines using new mRNA-based therapeutics!

Never let a good crisis go to waste. – Winston Churchill

Perhaps doctors will prescribe antidepressants, too. But, the onslaught of new ‘OVID’ drug ads, such as this 90-second commercial for PAXLOVID, is upon us.

Why not do away with new neuro-medical diagnoses and call it what it is; Vacinosis?

Could the world of science be creating a new normal?  Is Sick the new Healthy? Is the media weaponizing healthy people?

By design, science is set up to quantify and commodify all human life, so quality of life is ignored.

If  acceptable “adverse events” from medical products include personality changes, loss of sensitivity, loss of memory, loss of mobility, and loss of immunity, does that not equate to loss of identity, loss of freedom, and loss of humanity?

Of Mice and Men

imageRobert Owen-Wahl from Pixabay” width=”300″ height=”223″>

Most people know the book, “Of Mice and Men.” Fewer know that the book was based on a poem, titled, To A Mouse, On Turning her up in her Nest, with the Plough, November 1785. by Robert Burns.

In scientific and experimental terms, there are often two subjects; mice and men.

Mice are small, easily frightened, easily defeated.
Men in are huge, fearless, deadly.
Mice = quiet and passive.
Men = outspoken, aggressive.

Reflect before you inject.

It is important to investigate the existing databases and do your own research. Know that the numbers are likely the tip of the AE iceberg since many injuries are never reported.

  1. VAERS 
  2. PubMed
  3. Vaccine Injury Compensation Database
  4. Europe PMC

For humans to remain part of Humanity, they will first need to know they are not mice.




Radiation Levels of Various Smartphones

Radiation Levels of Various Smartphones

Radiation Levels of Various Smartphones

by Matt Landman

If everyone were asked to list their most frequently used piece of technology, smartphones would be the unanimous winner. Their capabilities make them devices we frequently reach for during the day and are often never far from them. In fact, a 2021 survey found that more than half of all respondents spent 5-6 hours on their phones each day, not including any smartphone use due to work.

The consensus is clear, smartphones are highly used devices. However, smartphones also emit a small amount of EMF radiation, meaning their frequent use can expose you to radiation for hours each day.

Continue reading to learn more about the radiation limits on smartphones, which phones give off the most and least radiation, and what you can do to lessen this exposure.

Radiation Emitted by Smartphones

Mobile devices, including smartphones, emit a small amount of radiofrequency (RF) radiation at all times. This is how they send and receive their signals from cell towers. However, whether you’re using your phone or have the phone near your body, you can also absorb this radiation.

While any part of your body near the phone can absorb this radiation, of greatest concern is how this radiation exposure may impact your brain and central nervous system since smartphones are often used close to the head.

These worries are not unsubstantiated. Ionizing radiation has been shown to cause some brain cancers, and while ionizing radiation is a higher-energy radiation than RF radiation, there is still concern about the effects of frequent and long-term RF radiation from using cell phones and if it may cause similar cancers to develop.

The SAR Value

The Specific Absorption Rate (SAR) is the parameter used to measure radiation emission in phones. The SAR is also limited, with a cutoff level that all cell phone radiation emissions must fall under for the smartphone to be deemed safe.

The radiation standards for cell phones produced in the United States have been set at 1.6 W/Kg by the Federal Communications Commission (FCC), meaning any phone with a SAR value above this limit could be hazardous to your health.

However, even though all the popular smartphones on the market fall under this limit, they still offer exposure to radiation, with some having higher radiation emissions than others. For those looking to limit their EMF radiation exposure, opting for a phone with a lower SARS value may be a good idea.

Ranking Smartphones by SAR Value

The following are 12 smartphone models available today, ordered from highest to lowest SAR value.

  1. Samsung Galaxy S23 (1.58)
  2. OnePlus 11 (1.19)
  3. Apple iPhone 14 Pro (1.15)
  4. Google Pixel 7 Pro (1.09)
  5. Samsung Galaxy Z Flip4 (1.02)
  6. Apple iPhone 13 Pro (0.99)
  7. Google Pixel 6a (0.99)
  8. Samsung Galaxy S23 Ultra (0.96)
  9. Nokia C21 Plus (0.40)
  10. LG V60 ThinQ 5G (0.35)
  11. Samsung Galaxy S10 Plus (0.26)
  12. Samsung Galaxy Note 8 DUOS (0.17)

Of note, the Samsung Galaxy S23 has the highest SAR value by far and only just falls under the SAR limit. This makes the Samsung Galaxy S23 the worst phone on the market in regard to how much radiation is emitted.

However, Samsung has also created the phone with the lowest SAR value, the Samsung Galaxy Note 8 DUOS. For those looking for a cell phone with the lowest radiation, this is the best option.

How To Limit RF Radiation Exposure

Beyond changing out your smartphone for a model that emits less radiation, there are other steps you can take to lessen the amount of RF radiation you are exposed to:

Spend Less Time on Your Phone

First and foremost, spending less time on your phone, and keeping it away from your body when you’re not using it, lessens the amount of RF radiation you are exposed to each day.

Use Speakerphone

The amount of radiation absorbed by the body is greatest when the radiation-emitting device (i.e., the smartphone) is in direct contact with the skin. Because of this, using speakerphone instead of holding the phone to your head keeps the RF radiation away from your body and lessens your exposure.

Use Protective Covers

Smartphones can emit RF radiation even when not in use, which is why EMF protective covers can be a great way to lessen their impact and further decrease the exposure you get.

Overall, radiation from smartphones is an unavoidable daily occurrence, but being aware of your phone’s SAR value, lessening your smartphone usage, and keeping your phone away from your body by using speakerphone or EMF cell phone pouches can help lessen your daily exposure.

References

Time spent on average on a smartphone in the U.S. 2021 | Statista. (2023). https://www.statista.com/statistics/1224510/time-spent-per-day-on-smartphone-us/

Cell Phones and Specific Absorption Rate. https://www.fcc.gov/general/cell-phones-and-specific-absorption-rate

Matt’s Bio:

Through grassroots activism, film, interviews, and international summits, Matt has gained recognition as a leader in 5G and geoengineering/chemtrail awareness activism. Matt presents unprecedented and view-changing information directly from official documentation and accepted research. 

Matt Landman created the social change documentary Frankenskies, bringing awareness to ongoing atmospheric aerosol injections, chemtrails, weather modification programs and geoengineering. Matt has hosted a series of conferences, events and protests concerning the questions surrounding chemtrails and relentlessly continues to speak out against the ongoing lies in our skies.

In 2018 he hosted the third Global Summit to Stop Geoengineering in Tucson Arizona, protesting the SCOPEX sky-dimming experiment, after which the experiment was placed on ongoing hiatus.

In addition, Matt continues to contest varied Telecom networks with efforts to help citizens locally fight the rollout of the dangerous and disputed 5G data network in their communities. 

He is also currently working on a sequel film titled Frankenskies 2 : Climate Chains, which exposes the false narrative behind climate change and how weather modification programs combined with smart technology and media control will result in humanity’s enslavement if gone unchecked.

Matt is now leading a movement to protect humanity from harmful electromagnetic frequencies with his new project, EMF-shielded SPERO Protection Clothing. Matt aims to offer protection from the dangers of 5G and EMF radiation, before the technology hits widespread adoption. He was inspired to create this clothing and accessory line when he saw the need for protection of pregnant women and newborn children. This, combined with his own EMF sensitivities, gave rise to the vision of creating a brand that encompassed protecting both infants and adults through protective gear.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

420 with CNW — Proposed California Law Could Legalize Marijuana Cafes

image

The wave of cannabis reform that has swept across America over the past two decades doesn’t seem to be stopping any time soon. By April 2023, nearly 40 states had medical marijuana markets while close to two dozen states allowed recreational cannabis sales.

California legalized recreational cannabis in November 2016 and was soon generating billions of dollars in revenue and state tax from adult-use cannabis sales. With California now home to what is undoubtedly the largest cannabis market in the world, state lawmakers are currently working on a bill that would legalize marijuana cafes and allow the sale of both nonalcoholic drinks and food in legal cannabis retail establishments.

California’s state assembly recently passed a bill to legalize cannabis cafes in the state in a 59 to 9 vote before pushing the legislation to the Senate for discussion.

Such businesses started popping up in California a couple of years ago in regions such as Palm Springs, West Hollywood and San Francisco. Even smaller cities such as Ojai considered marijuana cafes as a means of boosting tourism and tax revenue in the wake of the coronavirus pandemic and subsequent lockdowns.

However, California law banned indoor smoking at the time and had regulations designed to keep workplaces smoke free for the health of employees.

Brad Rowe, a University of California, Los Angeles adjunct professor of cannabis policy, said in 2019 that the marijuana cafe segment was in its infancy and still mired with plenty of legal complications. The recent law could clear up most of these complications and allow the segment to grow without any regulatory obstacles.

Speaking on the floor, bill sponsor Assemblymember Matt Haney noted that the cannabis industry is currently struggling under the weight of high taxes, a surging black market and an oversaturated space.

California’s cannabis black market has proven to be an especially tough problem to solve as a large portion of the population still prefers to buy cheaper cannabis from black market dealers. Coupled with high taxes from the state and an oversupply of sellers in the market, many small cannabis businesses are struggling to stay afloat.

The new bill would provide businesses in the cannabis space with a new avenue for generating revenue via the sale of noncannabis, prepackaged soft drinks and foods at licensed consumption lounges or cafes. However, the bill prohibits the sale and consumption of alcohol and tobacco at cannabis consumption lounges. It would, however,  allow live performances in cannabis lounges and the sale of performance tickets to the public.

If this proposal becomes law, it could inject new life into struggling cannabis companies, and they, in turn, could ramp up their production to meet the increased demand for marijuana products. When such a rise in demand materializes, the benefits could trickle down to entities that are in the business of manufacturing the equipment used to grow marijuana, such as Advanced Container Technologies Inc. (OTC: ACTX).

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Dynaleo Inc, Dynaleo Group Services Inc. filed a Notice of Intention to Make a Proposal

Dynaleo Inc, Dynaleo Group Services Inc. filed a Notice of Intention to Make a Proposal

SOLICITATION FOR OFFERS

On May 23, 2023, Dynaleo Inc. and Dynaleo Group Services Inc. (collectively, the “Companies”) filed a Notice of Intention to Make a Proposal (the “NOI”) pursuant to Section 50.4(1) of the Bankruptcy and Insolvency Act (Canada), R.S.C. 1985, c. B-3 (the “BIA”) and Harris & Partners Inc. was appointed as Proposal Trustee of the Company (the “Proposal Trustee”). 

The Companies operate a premier, state-of-the-art, cannabis edibles facility located in Nisku, Alberta. The facility boasts several pieces of manufacturing equipment, including a complete candy processing line, packaging and labelling and a significant degree of tenant improvements. 

On May 30, 2023, the Court of Kings Bench of Alberta granted an order (the “SISP Order”) permitting the Companies and the Proposal Trustee to commence a Sale and Investment Solicitation Process (“SISP”). The SISP is being conducted in accordance with the procedures included in the SISP Order, which can be found on the Proposal Trustee’s website: www.hpiadvisory.com/dynaleo

Interested parties who wish to pursue a potential investment or acquisition are required to execute a Non-Disclosure Agreement to receive access to the data room.

Per the SISP, non-binding letters of intent must be submitted by no later than 5:00 pm (Calgary Time) on June 23, 2022 (Phase 1 Bid Deadline).

Sponsored Content by: Harris & Partners


Kentucky to Inject $42M into Psychedelic Research

The state of Kentucky joins the growing number of regions that are investing in psychedelics by injecting tens of millions of dollars into researching the therapeutic potential of hallucinogens in substance use disorders. More specifically, Kentucky is investing more than $40 million in psychedelic research as part of its efforts to curb the growing opioid addiction crisis.

Kentucky Attorney General Daniel Cameron said in a recent Kentucky Opioid Abatement Advisory Commission (KYOAAC) news conference that the commission wanted to investigate novel treatments for people suffering from opioid use disorder. The commission was formed in 2022 to distribute more than $842 million, which was part of a larger $26 billion settlement from large pharmaceutical companies due to the role they played in causing the opioid crisis.

Since the 1990s, America has been in the grip of an opioid crisis that has taken more than half a million lives and affected millions of Americans. Kentucky has been especially affected by the opioid epidemic and recently experienced an all-time fatality rate of 2,250 deaths from overdoses due to the coronavirus pandemic and a surge of black-market fentanyl into the market.

Cameron noted during the meeting that Kentucky loses more than 2,000 residents each year to addiction and stressed that this “cannot continue.” The commission announced that its new grant proposal was meant to study novel treatments that could “reverse the chemical effects” caused by opioid addiction and withdrawal.

According to KYOAAC chairman Bryan Hubbard, the state must use “any and all means” to tackle the opioid pandemic that takes thousands of Kentuckians’ lives each year. He said that the next phase of the fight against opioid addiction will involve investigating therapies that have breakthrough potential to create new treatments that could completely cure opioid dependence and give people a new lease on life.

This will involve providing $42 million to support research into the therapeutic potential of ibogaine for the next six years until the psychedelic goes through the FDA drug approval process. Ibogaine is a natural psychedelic produced by a Western African shrub called iboga that has traditionally been used in initiation rituals and healing ceremonies by specific communities in the region.

Although the drug is currently outlawed by the FDA, studies have found that it has the potential to treat addiction in patients with opioid use disorder. However, most of these studies have been limited to small sample size, and most researchers say that more research is needed to fully understand the effect of ibogaine on substance abuse disorders.

As Kentucky focuses on studying the therapeutic potential of ibogaine, other nonstate actors elsewhere, such as Field Trip Health Ltd. (OTC: FTHWF) (TSX: FTHW), are also engaged in studying other psychedelic compounds. The goal is to develop medicines for other mental health conditions for which current treatments aren’t providing the desired relief to many of those diagnosed with psychiatric ailments.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.